Abstract: Pharmaceutical combinations and methods for using such combinations to treat depression are disclosed. In various embodiments the pharmaceutical combinations include combinations of omega-3 fatty acids, pharmacological sleep agents, and non-pharmacological sleep therapies, and may include other ingredients such as antidepressants. The present invention relates pharmaceutical combinations and methods for their use to treat depression.

Abstract: The present invention provides a computerized system and method for controlling a user interface to provide for asymmetrical, preferential scheduling of appointments on an incentivized basis. The system may be used, for example, by health plan operators to incentivize healthcare/medical providers to provide treatment to patients that are members of the health plan, to ensure treatment is rendered in better alignment with each individual patient's or plans' needs. Further, the system may be used by health plan operators to incentivize healthcare/medical providers to promote rendering of care in a manner providing better patient outcomes, or otherwise better meeting objectives of the health plan operator. Further still, the system may be used to provide financial or other reward to providers for better of faster care to patients. Other advantages including providing improved patient access to needed healthcare/medical resources, and the ability to align incentives with dynamic payment tools.

Abstract: Pharmaceutical combinations and methods for using such combinations to treat depression are disclosed. In various embodiments (he pharmaceutical combinations include combinations of omega-3 fatty acids, pharmacological sleep agents, and non-pharmacological sleep therapies, and may include other ingredients such as antidepressants. The present invention relates pharmaceutical combinations and methods for their use to treat depression.

Abstract: A computerized system and method for providing a user interface and system for managing scheduling of tasks on a capacity-driven basis that improves the efficiency of use of limited resources, and can reverse the typical balance of power and negotiation leverage, for example, in medical/healthcare provider and patient/consumer transactions. Providers can determine pricing, but Consumers can be notified of changes in capacity (e.g., due to appointment cancellations) that favor the patient/consumer, and present an opportunity for discounted pricing, while also allowing the provider to avoid a lost revenue opportunity. The system is structured to serve multiple unaffiliated providers, so that consumer demand and provider capacity may be matched across multiple providers, which is atypical in particular for medical/healthcare providers.

Abstract: Described herein are computer-implemented techniques for delivering and administering adaptive, personalized care to patients suffering from mental disorders and illnesses that create a risk of suicide. Some aspects described herein provide a computer-implemented method for administering treatment activities to treat a patient who is at risk of dying by suicide. For example, a patient's device (e.g., mobile phone, tablet, computer, etc.) may select and administer one or more treatment activities to reduce the patient's risk of suicide. Some aspects described herein provide a computer-implemented method for adapting treatment for a patient based on patient data, and administering the adapted treatment to the patient. For example, a patients device may obtain the patient data and adapt and administer the treatment. Some aspects described herein provide a system for delivering adaptive treatment of mental disorders and illnesses over a communication network to one or more devices.

Abstract: A system and method for development and management of a trusted support network for an at-risk person. The system provides a computerized interface providing the at-risk person with both synchronous and asynchronous support, to ensure that the at-risk person is adequately supported at critical times to lessen the risk of harm. The system provides for training of laypersons, so that a layperson can provide effective support and intervention to avert adverse outcomes for such an at-risk person. Further, the system provides for communication among multiple members of a support team. Further still, the system provides for delivery of not only person-to-person supportive communications, but also automated composition and/or delivery of supportive communications. Accordingly, the system can cause display of notices/notifications/alerts and/or placing of telephone calls, sending of text messages, etc. and provide communications in lieu of, or in addition to, those from a supporter.

Abstract: Described herein are computer-implemented techniques for delivering and administering adaptive, personalized care to patients suffering from mental disorders and illnesses (including those creating a risk of suicide). Some aspects described herein provide a computer-implemented method for adapting treatment for a patient based on patient data, and administering the adapted treatment to the patient. For example, a patient's device may obtain the patient data and adapt and administer the treatment. Some aspects described herein provide a system for delivering adaptive treatment of mental disorders and illnesses over a communication network to one or more devices. Some aspects described herein provide a computer-implemented method for administering treatment activities to treat a patient who is at risk of dying by suicide. For example, a patient's device (e.g., mobile phone, tablet, computer, etc.) may select and administer one or more treatment activities to reduce the patient's risk of suicide.

Abstract: A system and method for patient assessment using disparate data sources and data-informed clinician guidance via a shared patient/clinician user interface. The interface can be offered in person, with both patient and clinician in the same physical environment, or with each of them in different locations, using computerized devices linked via a communications network and/or a telehealth interface. The system guides the clinician in a collaborative way that ensures fidelity to a proper and high-quality clinical outcome, while retaining clinician-patient interactions and engagement. Accordingly, not every clinician is required to be a sub-specialist in a particular condition, such as suicide care, and a non-specialist clinician can perform an effective patient assessment because of the guidance provided by the system.

Abstract: Pharmaceutical combinations and methods for using such combinations to treat depression are disclosed. In various embodiments (he pharmaceutical combinations include combinations of omega-3 fatty acids, pharmacological sleep agents, and non-pharmacological sleep therapies, and may include other ingredients such as antidepressants. The present invention relates pharmaceutical combinations and methods for their use to treat depression.

Abstract: A system and method for capturing and analyzing a person's behavioral functions (e.g., 3-D bodily movements, facial expressions, vocalizations), and for developing a corresponding personal behavioral signature. The capture may be performed passively, e.g., in contactless manner (e.g., using LIDAR or camera-based imaging, and/or a microphone). Artificial intelligence, machine learning, and/or other techniques to may be used to analyze captured behavioral function data to identify patterns, assess characteristics, etc., and develop the corresponding behavioral signature. A baseline signature may be compared to a subsequent signature to assess a change in behavioral state. Similarly, data and/or signatures for multiple individuals having a common disease (or receiving a common treatment) may be analyzed to develop a characteristic disease signature (or treatment signature).

Abstract: A system and method for treatment efficacy-based evaluation of therapeutic products, and management of distribution of, and efficacy-based determination of payments for, such therapeutic products. A computerized therapeutics management system is provided that monitors a broad range of activities within a communications/data network to obtain relevant data, allow payors to define what types of therapeutic benefits/efficacy they value and are willing to pay for by selection of corresponding efficacy metrics, e.g., via a corresponding graphical user interface, using data from disparate sources to evaluate efficacy of therapeutic products using the payor-selected efficacy metrics, and then providing for payments to be established, and/or controlling payors' or other's systems to make payments, as a function of efficacy as measured by the payor-selected metrics. The system thereby improves the treatment of care for patients, an reduces overall health system costs.

Abstract: Pharmaceutical combinations and methods for using such combinations to treat depression are disclosed. In various embodiments (he pharmaceutical combinations include combinations of omega-3 fatty acids, pharmacological sleep agents, and non-pharmacological sleep therapies, and may include other ingredients such as antidepressants. The present invention relates pharmaceutical combinations and methods for their use to treat depression.

Abstract: Pharmaceutical combinations and methods for using such combinations to treat depression are disclosed. In various embodiments (the pharmaceutical combinations include combinations of omega-3 fatty acids, pharmacological sleep agents, and non-pharmacological sleep therapies, and may include other ingredients such as antidepressants. The present invention relates pharmaceutical combinations and methods for their use to treat depression.

Abstract: The present disclosure provides compositions, methods, systems, and apparatuses for treating disorders or illnesses. The composition may comprise at least one substance based on or derived from cocoa beans or coffee beans provided to be used in the methods, systems, and apparatuses and consumed by a patient for treatment of a disorder or illness. The systems and apparatuses, generally used in combination with the compositions, may comprise at least one device (e.g., a sensor) configured to monitor at least one action performed by a patient, and at least one processor.

Abstract: Pharmaceutical combinations and methods for using such combinations to treat depression are disclosed. In various embodiments (the pharmaceutical combinations include combinations of omega-3 fatty acids, pharmacological sleep agents, and non-pharmacological sleep therapies, and may include other ingredients such as antidepressants. The present invention relates pharmaceutical combinations and methods for their use to treat depression.

Abstract: Systems and methods are provided for offering promotional discounts, rebates, and other promotions to improve the utilization of unused inventory and to drive consumer patronage and loyalty. An electronic platform enables businesses and other entities to create and manage customer loyalty and promotional programs. The electronic platform enables businesses and other entities to track levels of patronage by customers in order to offer instant or retroactive rebates on an individual or group basis. The electronic platform further enables an entity to adjust the benefits, discounts, rebates, and promotions based on predetermined behavior, including tracking consumer activity and processing rebates or refunds based on the discounts. The electronic platform provides information systems and networks to track, monitor, and reserve resources. The electronic platform further provides database structures to track purchasing activity and apply varied pricing structures based on volume of usage during set time frames.

Abstract: The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein have contain greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using the dosage forms to treat a variety of cardiovascular, autoimmune, inflammatory, and central nervous system disorders by administering a formulation of the invention to a patient in need thereof.

Abstract: The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein have contain greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using the dosage forms to treat a variety of cardiovascular, autoimmune, inflammatory, and central nervous system disorders by administering a formulation of the invention to a patient in need thereof.

Abstract: Milk and/or yogurt fortified with lysozyme for augmentation of the immune system and aid the immune compromised.

Abstract: Homogenized, semi-solid food stuff fortified with lysozyme for augmentation of the immune system and to aid the immune compromised.